PCRRF yields 2.89% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, PCRRF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PCRRF + PFE for your $10,000?
Pasco Corporation engages in the acquisition, analysis, and provision of geospatial information in Japan and internationally. It offers spaceborne services that handle data from the commercial earth observation satellites launched worldwide; and airborne surveying services, such as aerial photography, aerial laser, thermal sensor, hyperspectral sensor, oblique aerial photography, and airborne IFSAR surveying, as well as portable aerial photography and locator systems. The company also provides vehicle/ground surveying services, including road condition laser, road condition, global positioning system, total station, precision, and terrestrial laser surveying, as well as ground based InSAR and radar; and water area surveying services comprising bathymetry and seabed exploration. In addition, it offers geographic information system (GIS) cloud services for the municipalities and central government, cloud-based regional analysis and marketing services for the private companies, and reassurance with disaster prevention systems; customization and GIS application development; and geospatial information consulting services, including regional strategy analysis, disaster prevention and mitigation consultant, road and bridge design, water supply and sewage facility management, dam and port management, rivers and erosion control, mapping solutions, and maintenance services. The company was formerly known as Pacific Koku Sokuryo Co., Ltd. and changed its name to Pasco Corporation in 1983. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Pasco Corporation is a subsidiary of Secom Co., Ltd.
Full PCRRF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.